ClinicalTrials.gg
Not yet recruitingNCT07499518FERTIOPKUpdated Jun 10, 2026

Fertility and Polycystic Ovary Syndrome

An observational study in Polycystic Ovary Syndrome (PCOS), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
473
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Polycystic Ovary Syndrome with a site in France — 9 open to participants now, 10 under way, 1 of them phase 3. Polycystic Ovary Syndrome · France.

Started
2026
with 4 others
Observational
8 of 21
3 open now
Registered
19th of 21
by date
Lead sponsor
3 of 21
Assistance Publique - Hôpitaux de Paris

Among the 21 studies in Polycystic Ovary Syndrome with a site in France, this one is one of 5 that started in 2026, is one of 8 observational ones, and was the 19th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

9 of the 21 studies in Polycystic Ovary Syndrome with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Polycystic Ovary Syndrome with a site in France, or all of them as a file.
02

Study summary

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age and affects approximately 10% of women worldwide. The diagnosis is based on the Rotterdam criteria established in 2003 and updated in the latest recommendations from the European Society of Human Reproduction (ESHRE) in 2023. The diagnosis of PCOS is based on the presence of 2 of the following 3 criteria:

  1. Oligo-anovulation
  2. Clinical and/or biological hyperandrogenism
  3. Polycystic ovary morphology (PCOM) on imaging It is also the leading cause of anovulatory infertility, with a 15-fold increased risk of infertility.

It is therefore a major cause of anovulatory infertility, but its pathophysiological mechanisms remain complex and multifactorial, involving interactions between genetic, metabolic, hormonal, and environmental factors. Prior to embarking on a fertility treatment plan, it is essential to better understand how these various factors influence ovarian function and reproductive capacity in patients with PCOS. Identifying and characterizing factors associated with fertility-such as hormonal profiles, insulin sensitivity, and metabolic markers-could help better predict future fertility and optimize personalized care and fertility outcomes. The aim of this study is therefore to identify modifiable factors influencing the fertility of PCOS patients phenotyped at La Pitié-Salpêtrière hospital.

03

Conditions studied

  • Polycystic Ovary Syndrome (PCOS)

Keywords

  • PCOS
  • Fertility
  • parental project
  • pregnancy
  • hormonal factors
  • metabolic factors
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

PCOS patients and healthy PCOS-free participants previously enrolled in METABOPK research at Pitié-Salpêtrière hospital

Eligibility criteria

Inclusion Criteria- PCOS group:

  • Aged between 18 and 45 years old
  • Female with a diagnosis of PCOS according to ESHRE criteria
  • Previouslu enrolled in METABOPK research

Inclusion Criteria- Control group

  • Aged between 18 and 45 years old
  • Female with normal metabolic and hormonal profiles
  • Previouslu enrolled in METABOPK research

Exclusion Criteria:

  • A prior diagnosis of type 1 or type 2 diabetes
  • A diagnosis of non-classical adrenal block
  • Use of hormonal therapy, oral antidiabetic medication, lipid-lowering medication, antihypertensive medication, , or spironolactone
  • Menopause or current pregnancy
  • Lack of data on , insulin levels, and fasting blood glucose
  • Patients who do not speak French
  • Patients under legal guardianship, conservatorship, or curatorship
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
473 participants (estimated)
Patient registry
No

Groups and cohorts

  • PCOS patients

    PCOS patients aged between 18 and 45 years

    Other: Questionnaires

  • Control

    Control (PCOS free)

    Other: Questionnaires

Interventions

  • OtherQuestionnaires

    Questionnaires about fertility and potential pregnancies

06

What researchers measure

Primary outcomes

  1. Description of the mode of conception

    Description of the mode of conception: spontaneous or induced; if induced, by which ART technique or following which treatment to improve PCOS symptoms (inositol, GLP-1 analog, metformin, lifestyle and dietary changes, etc.). These informations will be colected from medical records and frome the specific questionnaire.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Description of the treatment protocols for infertility

    Description of the treatment protocols for infertility among women in the cohort, if applicable: The description of infertility will be based on patient reports and treatment records

    Time frame: Through study completion, an average of 1 year

  2. Description of obstetric complications

    Description of obstetric complications: ectopic pregnancy, miscarriage, intrauterine fetal death, intrauterine growth restriction (IUGR), gestational diabetes, hypertension, preeclampsia, HELLP syndrome, intrahepatic cholestasis of pregnancy, gestational age at delivery, spontaneous or induced labor, birth weight, breastfeeding possible if desired: The description of obstetric complications will be based on data from the specific questionnaire and from pregnancy and delivery follow-up reports.

    Time frame: Through study completion, an average of 1 year

  3. Identification of hormonal and metabolic factors associated with infertility and obstetric complications

    Identify hormonal and metabolic factors associated with infertility and obstetric complications early on so that appropriate measures can be taken in preparation for starting a family

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
  • Endocrinology department, Pitié Salpêtrière hospital
    Paris, 75013, France
08

References and documents

Individual participant data

Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

Of 71 non-industry observational studies under Polycystic Ovary Syndrome, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 74 studies reached it within 14 months; a quarter within 6 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07499518
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jun 10, 2026

Study contacts

Anne BACHELOT, MD, PhD
Contact
anne.bachelot@aphp.fr
+33 01 42 16 02 46 ext. +33
Anne BACHELOT, MD-PhD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion